Kinnate BioPharma Inc.
We are a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Our mission is to expand the reach of targeted therapeutics by developing products for underserved populations. We utilize our deep expertise in structure-based drug discovery, translational research and patient-driven precision medicine, which we collectively refer to as our Kinnate Discovery Engine, to develop our targeted therapies.
Our most advanced product candidate is KIN002787, which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor we are developing for the treatment of patients with lung cancer, melanoma and other solid tumors.
(Note: The deal was upsized at pricing: 20 million shares (vs. 11.5 million filed) – priced at $20 (above the new range of $18-$19), after the deal was increased by 25 percent in an SEC filing on Dec. 2, 2020.)
|Address||11975 El Camino Real, Suite 101 San Diego, CA 92130|
|Phone Number||(858) 299-4699|
|View Prospectus:||Kinnate BioPharma Inc.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-26.1 mil (last 12 months)|
|Price range||$20.00 - $20.00|
|Est. $ Volume||$240.0 mil|
|Manager / Joint Managers||Goldman Sachs/ SVB Leerink/ Piper Sandler|
|Expected To Trade:||12/3/2020|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|